Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Stock Price & Analysis

2 Followers

5HZ1 Stock Chart & Stats

€4.32€0.00(-0.46%)

At close: Nov 10 5:30 PM GMT+1

Day’s Range: EUR 4.28 - EUR 4.34
52-Week Range: EUR 3.22 - EUR 5.90
Previous Close: EUR 4.34
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 5.02B
Enterprise Value: EUR 43.47B
Total Cash (Recent Filing): EUR 2.12B
Total Debt (Recent Filing): EUR 2.10B
Price to Earnings (P/E): ―
Beta: 0.61
Next Earnings: Mar 29, 2027 (Est.)
EPS Estimate: 0.07
Next Dividend Ex-Date: N/A
Dividend Yield: 0.36%

Bulls Say, Bears Say

Bulls Say

Low Leverage

Tigermed’s low leverage and sizable equity base provide financial flexibility through changing business conditions. Limited debt obligations should reduce balance-sheet strain, preserve capacity to fund operations, and support investment in clinical research capabilities over the next several quarters.

Positive Free Cash Flow

Positive free cash flow despite a reported net loss indicates that the core business is still generating meaningful cash internally. This supports liquidity, ongoing investment, and resilience, while reducing reliance on external financing during the next two to six months.

Operating Profitability

The company retains positive operating and EBITDA margins while revenue continues to grow modestly. This suggests the underlying service platform remains economically viable, even though below-the-line results weakened, and provides a base for recovery if execution and business mix improve.

Bears Say

TTM Net Loss

The shift from healthy annual profitability to a TTM net loss is a material deterioration in earnings quality. Sustained losses can weaken internal funding capacity, reduce returns to shareholders, and make future performance more dependent on restoring profitability across the business.

Gross Margin Compression

The multi-year decline in gross margin points to reduced pricing power or a less favorable service mix, rather than a single-period earnings fluctuation. If persistent, weaker gross economics could limit operating leverage and make revenue growth less valuable to shareholders.

Uneven Cash Conversion

Although cash generation remains positive, its recent decline and uneven multi-year pattern indicate that cash generation is not consistently scaling with reported earnings. Weaker conversion can constrain reinvestment flexibility and reduce the durability of the company’s financial resilience.

Hangzhou Tigermed Consulting Co., Ltd. Class H News

Tigermed Announces Frontage Privatization and Separation Agreements

The latest update is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ). Hangzhou Tigermed Consulting announced agreements connected with the proposed privatization and separation transaction involving

3d ago5HZ1 3347

Hangzhou Tigermed Publishes Unaudited Q3 2026 Report Under Hong Kong Rules

Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ) has provided an announcement. Hangzhou Tigermed Consulting Co., Ltd., a Hong Kong-listed clinical research and pharmaceutical services provider, has released

2w ago5HZ1 3347

Tigermed Warns Investors as Subsidiary Frontage Faces Trading Halt on Potential Takeover News

The latest update is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ). Hangzhou Tigermed Consulting has disclosed that trading in the shares of its Hong Kong-listed

3w ago5HZ1 3347

Tigermed Directors Fined Over Shareholding Disclosure Violations in China

Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ) has issued an announcement. Hangzhou Tigermed Consulting Co., Ltd., a leading Chinese clinical research and biopharmaceutical services group listed in

3w ago5HZ1 3347

Tigermed Sets Board Meeting to Approve Third-Quarter Results

The latest update is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ). Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for October 29, 2026,

3w ago5HZ1 3347

Tigermed Adjusts 2026 Restricted Share Incentive Scheme After Shareholder Approval

Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ) has shared an announcement. Hangzhou Tigermed Consulting has secured shareholder approval for its 2026 Restricted A Share Incentive Scheme, including

1M ago5HZ1 3347

Tigermed Shareholders Approve All Resolutions at 2026 Extraordinary Meetings

Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ) has provided an announcement. Hangzhou Tigermed Consulting Co., Ltd., a PRC-based contract research and clinical trial services provider listed via

1M ago5HZ1 3347

Tigermed Directors Face Regulatory Warning and Fines Over Disclosure Lapses

The latest announcement is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ). Hangzhou Tigermed Consulting has disclosed that its directors and controlling shareholders, Mr. Ye Xiaoping

2M ago5HZ1 3347

Tigermed Calls 2026 EGM to Reshape Capital Structure and Launch New Share Incentive Plan

The latest announcement is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ). Hangzhou Tigermed Consulting has called a third extraordinary general meeting for September 23, 2026,

2M ago5HZ1 3347

Tigermed Calls 2026 H Shareholders’ Meeting to Vote on Capital Reduction and New Buyback Mandate

An update from Hangzhou Tigermed Consulting Co., Ltd. Class H ( ($HK:3347) ) is now available. Hangzhou Tigermed Consulting has called a third H share class meeting for September 23,

2M ago5HZ1 3347

5HZ1 FAQ

What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?

Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was €3.22 and its highest was €5.90 in the past 12 months.

What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?

Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is €5.02B.

When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?

Hangzhou Tigermed Consulting Co., Ltd. Class H’s next earnings report is estimated for Mar 29, 2027 (not yet confirmed), which is in 137 days.

How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?

Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Oct 29, 2026. The company reported €0.023 earnings per share for the quarter, missing the consensus estimate of €0.042 by -€0.019.

Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?

According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Undervalued.

Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?

Hangzhou Tigermed Consulting Co., Ltd. Class H does not currently pay dividends.

What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?

Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.07.

How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?

Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.

What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?

Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of €0.023 in its last earnings report, missing expectations of €0.042. Following the earnings report the stock price went down -2.765%.

Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?

Currently, no hedge funds are holding shares in DE:5HZ1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description